Jefferson Health

Physician Profile

Manish Sharma, MD

Jefferson University Physician

Academic Title: Assistant Professor

Medical Oncology - Bone Marrow Transplant (Not Accepting New Patients)
Medical Oncology - Hematologic Malignancies (Not Accepting New Patients)
Medical Oncology (Not Accepting New Patients)

Office Locations

925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-2340

Medical Services

Board Certifications

  • Medical Oncology
  • Internal Medicine

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital


  • Ross University School of Medicine, Medical School


  • West Virginia University School of Medicine


  • West Virginia University School of Medicine


  • West Virginia University School of Medicine
  • MD Anderson Cancer Center, Houston, TX

Recent Publications

Genotype-guided dosing study of FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer

Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule

Taking a Measured Approach to Toxicity Data in Phase i Oncology Clinical Trials

Resampling the N9741 trial to compare tumor dynamic versus conventional end points in randomized phase II trials

KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer

Reverse warburg effect in a patient with aggressive B-cell lymphoma: Is lactic acidosis a paraneoplastic syndrome?

Severe irinotecan-induced toxicity in a patient with UGT1A1*28 and UGT1A1*6 polymorphisms

Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients

Estimation of renal cell carcinoma treatment effects from disease progression modeling

Models of excellence: Improving oncology drug development

Why RECIST works and why it should stay--reply to counterpoint.

RECIST: No longer the sharpest tool in the oncology clinical trials toolbox - Point/Counterpoint

Why RECIST works and why it should stay - Counterpoint

Dasatinib in previously treated metastatic colorectal cancer: A phase II trial of the University of Chicago Phase II Consortium

Resampling phase III data to assess phase II Trial designs and endpoints

Role of randomized phase III trials in an era of effective targeted therapies

Randomized phase II Trials: A long-term investment with promising returns

A phase i study of sirolimus and bevacizumab in patients with advanced malignancies

GI cancers in 2010: New standards and a predictive biomarker for adjuvant therapy

Fatal CMV pneumonitis in a lymphoma patient treated with rituximab